Alteogen Inc.
196170.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.76T
Close$
Share Statistics
| Market cap | $16.76 Trillion |
|---|---|
| Enterprise Value | $16.79 Trillion |
| Dividend Yield | $371.00 (0.15%) |
| Earnings per Share | $2652.97 |
| Beta | 0.97 |
| Outstanding Shares | 73,511,000 |
Return
| Return on Equity | 35.67% |
|---|---|
| Return on Assets | 25.86% |
| Return on Invested Capital | 22.96% |
Valuation & Multiples
| P/E Ratio | 76.49 |
|---|---|
| PEG | -41.15 |
| Price to Sales | 69.75 |
| Price to Book Ratio | 32.38 |
| Enterprise Value to Revenue | 66.11 |
| Enterprise Value to EBIT | 132.69 |
| Enterprise Value to Net Income | 87 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$475.96
Average shareholder expectationRevenue Estimate
$57.21 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$968.28
Average shareholder expectationRevenue Estimate
$113.97 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alteogen Inc.
161 employees
CEO: Soon-Jae Park ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical...